Aethlon Medical (AEMD) investor relations material

Product overview and differentiation

• Hemopurifier is a medical device designed to remove harmful viruses and cancer-related extracellular vesicles (EVs) from the bloodstream using a proprietary lectin-based filtration system.

• Device is compatible with standard hospital blood pumping equipment and typically treats patients in four-hour sessions.

• Only product known to specifically remove EVs, which are implicated in cancer metastasis, drug resistance, and immune suppression.

• Device has FDA Breakthrough Device designation for life-threatening viruses and oncologic conditions.

Clinical development and trial progress

• Current focus is on oncology, with a safety trial underway in Australia targeting patients receiving Keytruda or Opdivo.

• Trial is structured in three cohorts, with progression dependent on Data Safety Monitoring Board approval; two cohorts completed, third pending.

• Preliminary data from the first cohort showed positive trends in target biomarkers.

• Australia was chosen for its world-class medical infrastructure and a 43% cash reimbursement incentive for clinical trial spending.

Market opportunity and scalability

• Addressable market is significant, as even a small improvement in response rates for major oncology drugs could impact large patient populations.

• 173 Hemopurifier treatments have been administered to 44 patients with no serious device-related adverse events.

• Manufacturing is scalable, with current capacity sufficient for ongoing trials and ability to ramp up as needed.